T Linka1, B W Müller, S Bender, G Sartory, M Gastpar. 1. Clinic for Psychiatry and Psychotherapy, Rheinische Kliniken Essen, University of Duisburg-Essen, Essen, Germany. thomas.linka@uni-essen.de
Abstract
INTRODUCTION: The intensity (loudness)-dependent amplitude change (IDAP) of auditory evoked event-related potential (ERP) components has been suggested as an indicator of central serotonergic neurotransmission. In patients with major depression, associations of high IDAP with favorable SSRI treatment outcome have been reported. This is the first study to assess the predictive value of the IDAP in SNRI treatment. METHODS: We evaluated the pre-treatment intensity-dependent change of auditory evoked P1, N1, P2, and P1/N1 and N1/P2 peak-to-peak amplitudes in 14 inpatients with major depressive episode (DSM IV) in the course of 24 days of treatment with the SNRI reboxetine (6-12 mg/d). RESULTS: Our data revealed a highly significant correlation between lower intensity-dependent N1 amplitude slopes prior to reboxetine treatment and stronger decrease of HDRS total score at Fz ( r = 0.86, P < 0.001), Fcz ( r = 0.91, P < 0.001), and Cz ( r = 0.93, P < 0.001). CONCLUSION: This result corroborates the hypothesis of the IDAP as a differential indicator of serotonergic versus noradrenergic antidepressant psychopharmacotherapy.
INTRODUCTION: The intensity (loudness)-dependent amplitude change (IDAP) of auditory evoked event-related potential (ERP) components has been suggested as an indicator of central serotonergic neurotransmission. In patients with major depression, associations of high IDAP with favorable SSRI treatment outcome have been reported. This is the first study to assess the predictive value of the IDAP in SNRI treatment. METHODS: We evaluated the pre-treatment intensity-dependent change of auditory evoked P1, N1, P2, and P1/N1 and N1/P2 peak-to-peak amplitudes in 14 inpatients with major depressive episode (DSM IV) in the course of 24 days of treatment with the SNRI reboxetine (6-12 mg/d). RESULTS: Our data revealed a highly significant correlation between lower intensity-dependent N1 amplitude slopes prior to reboxetine treatment and stronger decrease of HDRS total score at Fz ( r = 0.86, P < 0.001), Fcz ( r = 0.91, P < 0.001), and Cz ( r = 0.93, P < 0.001). CONCLUSION: This result corroborates the hypothesis of the IDAP as a differential indicator of serotonergic versus noradrenergic antidepressant psychopharmacotherapy.
Authors: I Hui Lee; Yen Kuang Yang; Po See Chen; Hui Chun Huang; Tzung Lieh Yeh; Ru-Band Lu; Nan-Tsing Chiu; Wei Jen Yao; Shih-Hsien Lin Journal: Psychopharmacology (Berl) Date: 2010-11-12 Impact factor: 4.530
Authors: Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter Journal: J Psychiatr Res Date: 2020-02-26 Impact factor: 4.791
Authors: Craig E Tenke; Jürgen Kayser; Pia Pechtel; Christian A Webb; Daniel G Dillon; Franziska Goer; Laura Murray; Patricia Deldin; Benji T Kurian; Patrick J McGrath; Ramin Parsey; Madhukar Trivedi; Maurizio Fava; Myrna M Weissman; Melvin McInnis; Karen Abraham; Jorge E Alvarenga; Daniel M Alschuler; Crystal Cooper; Diego A Pizzagalli; Gerard E Bruder Journal: Psychophysiology Date: 2017-01 Impact factor: 4.016
Authors: Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff Journal: Am J Psychiatry Date: 2018-10-03 Impact factor: 18.112
Authors: Madhukar H Trivedi; Patrick J McGrath; Maurizio Fava; Ramin V Parsey; Benji T Kurian; Mary L Phillips; Maria A Oquendo; Gerard Bruder; Diego Pizzagalli; Marisa Toups; Crystal Cooper; Phil Adams; Sarah Weyandt; David W Morris; Bruce D Grannemann; R Todd Ogden; Randy Buckner; Melvin McInnis; Helena C Kraemer; Eva Petkova; Thomas J Carmody; Myrna M Weissman Journal: J Psychiatr Res Date: 2016-03-15 Impact factor: 4.791